Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.73 |
| ▸ | HCK | P08631 | 6/20 | 0.73 |
| ▸ | TEK | Q02763 | 6/20 | 0.73 |
| ▸ | LCK | P06239 | 6/20 | 0.73 |
| ▸ | EGFR | P00533 | 5/20 | 0.73 |
| ▸ | ABL1 | P00519 | 4/20 | 0.73 |
| ▸ | KDR | P35968 | 4/20 | 0.73 |
| ▸ | LYN | P07948 | 3/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | PAK4 | O96013 | 2/20 | 0.73 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.73 |
| ▸ | INSR | P06213 | 2/20 | 0.73 |
| ▸ | CSF1R | P07333 | 2/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.73 |
| ▸ | MARK3 | P27448 | 2/20 | 0.73 |
| ▸ | FLT4 | P35916 | 2/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.73 |
| ▸ | BLK | P51451 | 2/20 | 0.73 |
| ▸ | NEK2 | P51955 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465500 | 1.00 | SRC (0.73) | SRCHCKTEKLCKEGFR | |
| SCHEMBL23847631 | 0.92 | SRC (0.77) | SRCHCKTEKLCKEGFR | |
| SCHEMBL23854962 | 0.92 | SRC (0.77) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6458929 | 0.89 | HCK (0.67) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6461325 | 0.88 | TEK (0.69) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6458140 | 0.88 | HCK (0.66) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6458138 | 0.88 | HCK (0.66) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6460275 | 0.88 | HCK (0.66) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6465081 | 0.88 | TEK (0.69) | SRCHCKTEKLCKEGFR | |
| SCHEMBL6461329 | 0.88 | TEK (0.69) | SRCHCKTEKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | SRC 46/4885HCK 107/4885TEK 1465/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | SRC 206/4885HCK 968/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.